Table 1.
Baseline characteristics of the study population (n = 83) within the KARISMA clinical trial of low-dose tamoxifen
| Characteristic | Overall |
|---|---|
| Age, mean years (SD) | 51.9 (10.0) |
| BMI, mean kg/m2 (SD) | 25.4 (4.1) |
| Menopausal status, n (%) | |
| Premenopausal, n (%) | 48 (57.8) |
| Postmenopausal, n (%) | 35 (42.2) |
| Mammographic density at baseline, mean cm2 (SD) | 42.0 (24.1) |
| Stromal area at baseline, mean % (SD) | 58.6 (20.0) |
| Epithelial area at baseline, mean % (SD) | 6.7 (6.6) |
| Adipose area at baseline, mean % (SD) | 34.6 (21.0) |
| Organised collagen composition, total area of biopsy | |
| Birefringence total area, mean % (SD) | 46.6 (20.4) |
| Thin fibre total area, mean % (SD) | 10.3 (5.6) |
| Intermediate fibre area, mean % (SD) | 16.1 (9.7) |
| Thick fibre area, mean % (SD) | 20.2 (10.9) |
| Missing, n (%) | 3 (3.6%) |
| Organised collagen composition, proportions of birefringence | |
| Thin fibre area of birefringence, mean % (SD) | 29.0 (22.7) |
| Intermediate fibre area of birefringence, mean % (SD) | 30.8 (12.7) |
| Thick fibre area of birefringence, mean % (SD) | 40.2 (12.6) |
| Missing, n (%) | 3 (3.6%) |
BMI Body mass index, SD Standard deviation